Isobutyrylcarnitine as a Biomarker of OCT1 Activity and Interspecies Differences in its Membrane Transport

被引:18
作者
Jensen, Ole [1 ]
Matthaei, Johannes [1 ]
Klemp, Henry G. [2 ]
Meyer, Marleen J. [3 ]
Brockmoller, Jurgen [1 ]
Tzvetkov, Mladen V. [3 ]
机构
[1] Univ Med Ctr Gottingen, Inst Clin Pharmacol, Gottingen, Germany
[2] Univ Med Ctr Gottingen, Inst Pediat & Adolescent Med, Gottingen, Germany
[3] Univ Med Greifswald, Inst Pharmacol, Ctr Drug Absorpt & Transport C DAT, Greifswald, Germany
关键词
OCT1; isobutyrylcarnitine; efflux; organic cation transporter; carnitine; Biomarker; ORGANIC CATION TRANSPORTER; ENDOGENOUS BIOMARKERS; FUNCTIONAL EXPRESSION; L-CARNITINE; IDENTIFICATION; PHARMACOKINETICS; POLYMORPHISMS; CLONING; REVEAL; METABOLISM;
D O I
10.3389/fphar.2021.674559
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Genome-wide association studies have identified an association between isobutyrylcarnitine (IBC) and organic cation transporter 1 (OCT1) genotypes. Higher IBC blood concentrations in humans with active OCT1 genotypes and experimental studies with mouse OCT1 suggested an OCT1-mediated efflux of IBC. In this study, we wanted to confirm the suggested use of IBC as an endogenous biomarker of OCT1 activity and contribute to a better understanding of the mechanisms behind the association between blood concentrations of carnitine derivatives and OCT1 genotype. Blood and urine IBC concentrations were quantified in healthy volunteers regarding intra- and interindividual variation and correlation with OCT1 genotype and with pharmacokinetics of known OCT1 substrates. Furthermore, IBC formation and transport were studied in cell lines overexpressing OCT1 and its naturally occurring variants. Carriers of high-activity OCT1 genotypes had about 3-fold higher IBC blood concentrations and 2-fold higher amounts of IBC excreted in urine compared to deficient OCT1. This was likely due to OCT1 function, as indicated by the fact that IBC correlated with the pharmacokinetics of known OCT1 substrates, like fenoterol, and blood IBC concentrations declined with a 1 h time delay following peak concentrations of the OCT1 substrate sumatriptan. Thus, IBC is a suitable endogenous biomarker reflecting both, human OCT1 (hOCT1) genotype and activity. While murine OCT1 (mOCT1) was an efflux transporter of IBC, hOCT1 exhibited no IBC efflux activity. Inhibition experiments confirmed this data showing that IBC and other acylcarnitines, like butyrylcarnitine, 2-methylbutyrylcarnitine, and hexanoylcarnitine, showed reduced efflux upon inhibition of mOCT1 but not of hOCT1. IBC and other carnitine derivatives are endogenous biomarkers of hOCT1 genotype and phenotype. However, in contrast to mice, the mechanisms underlying the IBC-OCT1 correlation in humans is apparently not directly the OCT1-mediated efflux of IBC. A plausible explanation could be that hOCT1 mediates cellular concentrations of specific regulators or co-substrates in lipid and energy metabolism, which is supported by our in vitro finding that at baseline intracellular IBC concentration is about 6-fold lower alone by OCT1 overexpression.
引用
收藏
页数:14
相关论文
共 53 条
  • [1] BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
  • [2] OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin
    Chen, Ligong
    Shu, Yan
    Liang, Xiaomin
    Chen, Eugene C.
    Yee, Sook Wah
    Zur, Arik A.
    Li, Shuanglian
    Xu, Lu
    Keshari, Kayvan R.
    Lin, Michael J.
    Chien, Huan-Chieh
    Zhang, Youcai
    Morrissey, Kari M.
    Liu, Jason
    Ostrem, Jonathan
    Younger, Noah S.
    Kurhanewicz, John
    Shokat, Kevan M.
    Ashrafi, Kaveh
    Giacomini, Kathleen M.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (27) : 9983 - 9988
  • [3] Chong Jasmine, 2019, Curr Protoc Bioinformatics, V68, pe86, DOI 10.1002/cpbi.86
  • [4] Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium
    Chu, Xiaoyan
    Liao, Mingxiang
    Shen, Hong
    Yoshida, Kenta
    Zur, Arik A.
    Arya, Vikram
    Galetin, Aleksandra
    Giacomini, Kathleen M.
    Hanna, Imad
    Kusuhara, Hiroyuki
    Lai, Yurong
    Rodrigues, David
    Sugiyama, Yuichi
    Zamek-Gliszczynski, Maciej J.
    Zhang, Lei
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (05) : 836 - 864
  • [5] Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions
    Chu, Xiaoyan
    Chan, Grace Hoyee
    Evers, Raymond
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (09) : 2357 - 2367
  • [6] Dynamic changes of plasma acylcarnitine levels induced by fasting and sunflower oil challenge test in children
    Costa, CCG
    De Almeida, IT
    Jakobs, C
    Poll-The, BT
    Duran, M
    [J]. PEDIATRIC RESEARCH, 1999, 46 (04) : 440 - 444
  • [7] EFFECT OF FASTING ON FREE AND ESTERIFIED CARNITINE LEVELS IN HUMAN-SERUM AND URINE - CORRELATION WITH SERUM LEVELS OF FREE FATTY-ACIDS AND BETA-HYDROXYBUTYRATE
    FROHLICH, J
    SECCOMBE, DW
    HAHN, P
    DODEK, P
    HYNIE, I
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1978, 27 (05): : 555 - 561
  • [8] Fukuda T, 2013, PHARMACOGENOMICS, V14, P1141, DOI [10.2217/PGS.13.94, 10.2217/pgs.13.94]
  • [9] An LC-MS/MS method to quantify acylcarnitine species including isomeric and odd-numbered forms in plasma and tissues
    Giesbertz, Pieter
    Ecker, Josef
    Haag, Alexander
    Spanier, Britta
    Daniel, Hannelore
    [J]. JOURNAL OF LIPID RESEARCH, 2015, 56 (10) : 2029 - 2039
  • [10] Cloning and characterization of two human polyspecific organic cation transporters
    Gorboulev, V
    Ulzheimer, JC
    Akhoundova, A
    UlzheimerTeuber, I
    Karbach, U
    Quester, S
    Baumann, C
    Lang, F
    Busch, AE
    Koepsell, H
    [J]. DNA AND CELL BIOLOGY, 1997, 16 (07) : 871 - 881